Alleh Lindquist
Co-Founder and Chief Executive OfficerFloraWorksAlleh Lindquist is the Co-Founder and Chief Executive Officer of
FloraWorks, a leading company in the cannabinoid industry. With a
passion for the hemp and cannabis sectors, Alleh has
spearheaded FloraWorks' mission to develop high-quality,
cannabinoid-based therapeutics. Under his leadership, the
company has focused on innovative research and the development
of rare and novel cannabinoids, such as their flagship product
TruCBNTM, which has shown promise in promoting better sleep
through rigorous clinical trials.
FloraWorks has completed a 1,020-person randomized, double-blind, placebo-controlled clinical trial and built a full GLP toxicology and genotoxicity package for its lead cannabinoid ingredient. FloraWorks is collaborating with advocacy groups, companies, and ACOs to develop a product-agnostic implementation layer for CMS program participation — structured patient intake, physician-guided dosing, drug interaction screening, real-world evidence tracking, and cost-effectiveness documentation — so ACOs can easily choose to participate and select viable products from qualifying suppliers.
Covered or Cut Off: Cracking Cannabis Insurance and Patient Access
Insurance remains one of the hardest walls between cannabis and the patients who need it. Despite expanding medical programs, most plans still refuse
Insurance remains one of the hardest walls between cannabis and the patients who need it. Despite expanding medical programs, most plans still refuse to cover cannabis products, leaving patients to pay out of pocket and pushing many toward the illic
Insurance remains one of the hardest walls between cannabis and the patients who need it. Despite expanding medical programs, most plans still refuse to cover cannabis products, leaving patients to pay out of pocket and pushing many toward the illicit market. For dispensary owners, medical professionals, and policymakers, this gap shapes pricing, demand, and trust across the entire sector.
This session confronts the access problem head-on. We
Insurance remains one of the hardest walls between cannabis and the patients who need it. Despite expanding medical programs, most plans still refuse to cover cannabis products, leaving patients to pay out of pocket and pushing many toward the illicit market. For dispensary owners, medical professionals, and policymakers, this gap shapes pricing, demand, and trust across the entire sector.
This session confronts the access problem head-on. We'll map the current reimbursement landscape, examine where coverage is slowly opening, and unpack the regulatory and federal barriers that keep insurers on the sidelines. You'll see how leading operators adapt cannabis retail strategies to serve cost-sensitive patients while staying inside cannabis business compliance lines.
The panelists connect access challenges to broader cannabis market trends, marijuana business funding pressures, and the cannabis industry opportunities emerging as policy shifts. You’ll leave this session with a clear, defensible plan for navigating coverage gaps and expanding patient access.
